-
Africa: PMI's Medicago to Supply 76 Million Doses of Covid-19 Vaccine Candidate
PMI, 26 October 2020
A Philip Morris International subsidiary is a shareholder in a biopharmaceutical company that reached agreements with two departments of the Canadian government to accelerate its… Read more »
-
Africa: Novel Coronavirus - How Close Are We to Treatment And Vaccine?
allAfrica, 17 March 2020
The new coronavirus, declared a pandemic on March 11 by the World Health Organisation (WHO) because of its global spread, and with more than 170,000 confirmed cases, according to… Read more »
Philip Morris International (Lausanne)
PMI's Medicago to Supply 76 Million Doses of Covid-19 Vaccine
Since 2008, Philip Morris Investments B.V. (PMIBV), a subsidiary of Philip Morris International (PMI) (NYSE: PM), has been a shareholder of Medicago (in which it currently holds an approximately one-third equity stake) and has supported Medicago's innovative plant-derived research and development focused on vaccines. The investment is consistent with PMI's own efforts to leverage science and innovation. Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC) is the majority shareholder and PMIBV's partner in Medicago. Among other things, PMIBV and MTPC will contribute additional funding to support Medicago's efforts to develop a COVID-19 vaccine candidate.
